{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:33:27Z","timestamp":1793727207829,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Columbia Technology Accelerator"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55421-5","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:04:49Z","timestamp":1735866289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5214-1572","authenticated-orcid":false,"given":"Hengrui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Zask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Forouhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3733-9556","authenticated-orcid":false,"given":"Sho","family":"Iketani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9380-0597","authenticated-orcid":false,"given":"Alana","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4995-5724","authenticated-orcid":false,"given":"Daniel R.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlya","family":"Habashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-240X","authenticated-orcid":false,"given":"Karenna","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Jung","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Lovett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-149X","authenticated-orcid":false,"given":"David D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-3868","authenticated-orcid":false,"given":"Brent R.","family":"Stockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"55421_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1126\/science.adi6511","volume":"380","author":"K Kupferschmidt","year":"2023","unstructured":"Kupferschmidt, K. & Wadman, M. End of COVID-19 emergencies sparks debate. Science 380, 566\u2013567 (2023).","journal-title":"Science"},{"key":"55421_CR2","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard, https:\/\/covid19.who.int (2023)."},{"key":"55421_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41591-023-02219-5","volume":"29","author":"JJ Lau","year":"2023","unstructured":"Lau, J. J. et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat. Med. 29, 348\u2013357 (2023).","journal-title":"Nat. Med."},{"key":"55421_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29413-2","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat. Commun. 13, 1891 (2022).","journal-title":"Nat. Commun."},{"key":"55421_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"55421_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368, 409\u2013412 (2020).","journal-title":"Science"},{"key":"55421_CR7","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"R Owen Dafydd","year":"2021","unstructured":"Owen Dafydd, R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"55421_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397\u20131408 (2022).","journal-title":"N. Engl. J. Med."},{"key":"55421_CR9","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"55421_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2023","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2023).","journal-title":"Nature"},{"key":"55421_CR11","doi-asserted-by":"crossref","unstructured":"Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. & Brosh-Nissimov, T. Nirmatrelvir resistance-de novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure-a Case Report. Clin. Infect. Dis. 78, 352\u2013355 (2024).","DOI":"10.1093\/cid\/ciad494"},{"key":"55421_CR12","doi-asserted-by":"crossref","unstructured":"Hirotsu, Y. et al. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2. Med. 4, 813\u2013824.e4 (2023).","DOI":"10.1016\/j.medj.2023.08.001"},{"key":"55421_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22362-2","volume":"12","author":"S Iketani","year":"2021","unstructured":"Iketani, S. et al. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nat. Commun. 12, 2016 (2021).","journal-title":"Nat. Commun."},{"key":"55421_CR14","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1021\/jm0603926","volume":"49","author":"S Yang","year":"2006","unstructured":"Yang, S. et al. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J. Med Chem. 49, 4971\u20134980 (2006).","journal-title":"J. Med Chem."},{"key":"55421_CR15","doi-asserted-by":"publisher","first-page":"34979","DOI":"10.1074\/jbc.M112.374504","volume":"287","author":"CC Valley","year":"2012","unstructured":"Valley, C. C. et al. The methionine-aromatic motif plays a unique role in stabilizing protein structure. J. Biol. Chem. 287, 34979\u201334991 (2012).","journal-title":"J. Biol. Chem."},{"key":"55421_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41589-021-00966-5","volume":"18","author":"F Rabe von Pappenheim","year":"2022","unstructured":"Rabe von Pappenheim, F. et al. Widespread occurrence of covalent lysine\u2013cysteine redox switches in proteins. Nat. Chem. Biol. 18, 368\u2013375 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"55421_CR17","doi-asserted-by":"crossref","unstructured":"Steuten, K. et al. Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID\u221219. ACS Infect. Dis. 7, 1457\u20131468 (2021).","DOI":"10.1021\/acsinfecdis.0c00815"},{"key":"55421_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 e278 (2020).","journal-title":"Cell"},{"key":"55421_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-021-00558-8","volume":"6","author":"M-M Zhao","year":"2021","unstructured":"Zhao, M.-M. et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct. Target. Ther. 6, 134 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"55421_CR20","doi-asserted-by":"crossref","unstructured":"Resnick, S. J. et al. Inhibitors of coronavirus 3CL proteases protect cells from protease-mediated cytotoxicity. J. Virol. 95, e0237420 (2021).","DOI":"10.1128\/JVI.02374-20"},{"key":"55421_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1152\/physrev.00039.2013","volume":"94","author":"VM Labunskyy","year":"2014","unstructured":"Labunskyy, V. M., Hatfield, D. L. & Gladyshev, V. N. Selenoproteins: molecular pathways and physiological roles. Physiol. Rev. 94, 739\u2013777 (2014).","journal-title":"Physiol. Rev."},{"key":"55421_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1021\/acscentsci.2c01359","volume":"9","author":"N Hou","year":"2023","unstructured":"Hou, N. et al. Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro. ACS Cent. Sci. 9, 217\u2013227 (2023).","journal-title":"ACS Cent. Sci."},{"key":"55421_CR23","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","volume":"65","author":"SH Han","year":"2022","unstructured":"Han, S. H. et al. Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CL(pro).J Med Chem 65, 2880\u20132904 (2022).","journal-title":"J Med Chem"},{"key":"55421_CR24","doi-asserted-by":"publisher","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","volume":"65","author":"S Gao","year":"2022","unstructured":"Gao, S. et al. Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity. J. Med Chem. 65, 13343\u201313364 (2022).","journal-title":"J. Med Chem."},{"key":"55421_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-023-01482-9","volume":"8","author":"Z Jiang","year":"2023","unstructured":"Jiang, Z. et al. Discovery of novel non-peptidic and non-covalent small-molecule 3CL(pro) inhibitors as potential candidate for COVID-19 treatment. Signal Transduct. Target Ther. 8, 209 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"55421_CR26","doi-asserted-by":"crossref","unstructured":"Herlah, B. et al. Design, synthesis and evaluation of fused bicyclo[2.2.2]octene as a potential core scaffold for the non-covalent inhibitors of SARS-CoV-2 3CL(pro) Main Protease. Pharmaceuticals 15, 539 (2022).","DOI":"10.3390\/ph15050539"},{"key":"55421_CR27","doi-asserted-by":"publisher","first-page":"20697","DOI":"10.1021\/jacs.1c08060","volume":"143","author":"C Ma","year":"2021","unstructured":"Ma, C. et al. Discovery of Di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity. J. Am. Chem. Soc. 143, 20697\u201320709 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"55421_CR28","doi-asserted-by":"crossref","unstructured":"Lockbaum, G. J. et al. Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188. Viruses 13, 174 (2021).","DOI":"10.3390\/v13020174"},{"key":"55421_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.128067","volume":"42","author":"JY Lee","year":"2021","unstructured":"Lee, J. Y. et al. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library. Bioorg. Med. Chem. Lett. 42, 128067 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"55421_CR30","doi-asserted-by":"crossref","unstructured":"Ferreira, J. C., Fadl, S. & Rabeh, W. M. Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2. J. Biol. Chem. 298, 102023 (2022).","DOI":"10.1016\/j.jbc.2022.102023"},{"key":"55421_CR31","doi-asserted-by":"publisher","first-page":"13894","DOI":"10.1074\/jbc.M510745200","volume":"281","author":"H Chen","year":"2006","unstructured":"Chen, H. et al. Only one protomer is active in the dimer of SARS 3C-like proteinase. J. Biol. Chem. 281, 13894\u201313898 (2006).","journal-title":"J. Biol. Chem."},{"key":"55421_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1021\/acscombsci.0c00058","volume":"22","author":"B Goyal","year":"2020","unstructured":"Goyal, B. & Goyal, D. Targeting the dimerization of the main protease of coronaviruses: a potential broad-spectrum therapeutic strategy. ACS Comb. Sci. 22, 297\u2013305 (2020).","journal-title":"ACS Comb. Sci."},{"key":"55421_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s43586-021-00084-5","volume":"2","author":"AL Satz","year":"2022","unstructured":"Satz, A. L. et al. DNA-encoded chemical libraries. Nat. Rev. Methods Prim. 2, 3 (2022).","journal-title":"Nat. Rev. Methods Prim."},{"key":"55421_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/2472555218808454","volume":"24","author":"Z Zhu","year":"2019","unstructured":"Zhu, Z. et al. Development of a selection method for discovering irreversible (covalent) binders from a DNA-encoded library. SLAS Discov. 24, 169\u2013174 (2019).","journal-title":"SLAS Discov."},{"key":"55421_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nchembio.2079","volume":"12","author":"K Shimada","year":"2016","unstructured":"Shimada, K. et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 12, 497\u2013503 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"55421_CR36","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.chom.2022.08.003","volume":"30","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. Cell Host Microbe 30, 1354\u20131362.e1356 (2022).","journal-title":"Cell Host Microbe"},{"key":"55421_CR37","doi-asserted-by":"publisher","unstructured":"Ye, C. et al. Rescue of SARS-CoV-2 from a single bacterial artificial chromosome. mBio 11, https:\/\/doi.org\/10.1128\/mBio.02168-20 (2020).","DOI":"10.1128\/mBio.02168-20"},{"key":"55421_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1107\/S0907444909047374","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr D. Biol. Crystallogr 66, 133\u2013144 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"55421_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1107\/S0907444909042589","volume":"66","author":"A Vagin","year":"2010","unstructured":"Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr D. Biol. Crystallogr 66, 22\u201325 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"55421_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/jsbi.1999.4094","volume":"125","author":"DE McRee","year":"1999","unstructured":"McRee, D. E. XtalView\/Xfit-A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125, 156\u2013165 (1999).","journal-title":"J. Struct. Biol."},{"key":"55421_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D. Biol. Crystallogr 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"55421_CR42","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.1073\/pnas.181342398","volume":"98","author":"NA Baker","year":"2001","unstructured":"Baker, N. A., Sept, D., Joseph, S., Holst, M. J. & McCammon, J. A. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc. Natl Acad. Sci. 98, 10037\u201310041 (2001).","journal-title":"Proc. Natl Acad. Sci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55421-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55421-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55421-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T02:04:07Z","timestamp":1735869847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55421-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55421"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55421-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.I., H.L., A.Z., F.F., B.R.S., A.C., and D.D.H. are inventors on a patent application submitted based on this work. B.R.S. is an inventor on additional patents and patent applications related to small molecule therapeutics, and co-founded and serves as a consultant to Exarta Therapeutics, and ProJenX Inc., serves as a consultant to Weatherwax Biotechnologies and Akin Gump Strauss Hauer & Feld LLP, and holds equity in Sonata Therapeutics. S.I. and D.D.H. have sponsored research agreements with Enanta Pharmaceuticals, Shionogi & Co., Ltd., and Regeneron Pharmaceuticals. D.D.H. is a co-founder of TaiMed Biologics and RenBio, consultant to WuXi Biologics, Brii Biosciences, Apexigen, and Veru Inc., and board director for Vicarious Surgical. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}